Drug Profile

ORIC 944

Alternative Names: ORIC-944

Latest Information Update: 09 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mirati Therapeutics
Developer Bayer; Janssen Research & Development; ORIC Pharmaceuticals
Class Antineoplastics; Small molecules
Mechanism of Action Polycomb repressive complex 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Prostate cancer

Most Recent Events

28 May 2025 Efficacy and adverse events data from the phase I/II trial in Prostate cancer released by ORIC Pharmaceuticals
28 Apr 2025 Pharmacodynamics data from a preclinical trial in Prostate cancer released by ORIC Pharmaceuticals
25 Feb 2025 ORIC Pharmaceuticals plans a registrational phase III trial for metastatic castration resistant Prostate cancer in the first half of 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com